Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII

In 2018, Refacto AF(R), a B-domain-deleted third-generation FVIII concentrate, became our preferential product. After the introduction, the development of inhibitors was prospectively monitored; retrospectively, we sought for risk factors in the patients who developed a de-novo inhibitor. Over a per...

Descripción completa

Detalles Bibliográficos
Autores principales: Hooimeijer, Louise H, Stein-Wit, Marjet A, Voskuilen, Marja AJ, Lukens, Michaël V, Meijer, Karina, Mäkelburg, Anja BU, Tamminga, Rienk YJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Manuscript
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068986/
https://www.ncbi.nlm.nih.gov/pubmed/36998198
http://dx.doi.org/10.1177/10760296231167416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068986/
https://www.ncbi.nlm.nih.gov/pubmed/36998198
http://dx.doi.org/10.1177/10760296231167416

Ejemplares similares